Radiation Skin Injury Care in Radiotherapy for Oncology: Mechanisms, Drug Therapy and Novel Biomaterial Application Strategies

被引：7

作者：

Wang, Yiren ^{[1
]}

Yang, Lei ^{[2
]}

Liu, Bo ^{[1
]}

Liao, Shuang ^{[1
]}

Fu, Xiao ^{[3
,4
]}

Zhou, Yun ^{[5
]}

Zhou, Ping ^{[6
]}

机构：

[1] Southwest Med Univ, Sch Nursing, Luzhou 646000, Peoples R China

[2] Southwest Med Univ, Affiliated Hosp, Dept Oncol, Luzhou 646000, Peoples R China

[3] Sichuan Univ, West China Sch Nursing, West China Hosp 2, Dept Pediat, 61000, Chengdu, Peoples R China

[4] Minist Educ, Key Lab Birth Defects & Related Dis Women & Childr, Chengdu 61000, Peoples R China

[5] Southwest Med Univ, Sch Med Informat & Engn, Luzhou 646000, Peoples R China

[6] Southwest Med Univ, Affiliated Hosp, Dept Radiol, Luzhou 646000, Peoples R China

来源：

ADVANCED THERAPEUTICS | 2023年 / 6卷 / 11期

关键词：

biomaterial; care measures; mechanism; radiation skin injury; synthetic strategy; MESENCHYMAL STEM-CELLS; IONIZING-RADIATION; GOLD NANOPARTICLES; CLINICAL-TRIAL; CANCER; DERMATITIS; OXIDE; RADIOSENSITIZATION; IRRADIATION; PREVENTION;

D O I：

10.1002/adtp.202300024

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Radiation skin injury (RSI) is a frequent adverse effect of radiation therapy for malignant tumors. It often leads to problems such as decreased quality of life in patients and interferes with the normal course of radiation therapy (RT). With the rising incidence of tumors and the burgeoning number of patients undergoing RT, the care of RSI is of crucial importance in cancer patient treatment. Currently, drugs and biomaterials are widely used in the care of RSI. However, there is no international consensus on the current protocol for the therapeutic care of RSI. Many drugs and biomaterials cannot be applied to the appropriate type of radiation dermatitis, resulting in unfavorable results in the therapeutic care of RSI. The choice of appropriate drugs and biomaterials for the therapeutic care of the different types of RSI is essential to improving the quality of life of patients. This article first reviews the main mechanisms of acute and chronic RSI. Subsequently, the application of drugs and novel biomaterials in the preventive, acute, and chronic phases of the care of RSI is summarized. Finally, the suggestions and protocols for the application of novel biomaterials in the care of RSI are discussed, as are the current challenges and future prospects for the development of combined biomaterials and integrated care solutions.

引用

页数：18

共 4 条

[1] Radiation therapy - Activation of gene transcription and the development of genetic radiotherapy - Therapeutic strategies in oncology
Kufe, D
Weichselbaum, R
CANCER BIOLOGY & THERAPY, 2003, 2 (04) : 326 - 329
[2] Challenges and opportunities for early phase clinical trials of novel drug-radiotherapy combinations: recommendations from NRG Oncology, the American Society for Radiation Oncology (ASTRO), the American College of Radiology (ACR), the Sarah Cannon Research Institute, and the American College of Radiation Oncology (ACRO)
Zumsteg, Zachary S.
Sheth, Siddharth
Jabbour, Salma K.
Patel, Krishnan R.
Kimple, Randall J.
Williams, Terence M.
Xu-Welliver, Meng
Torres-Saavedra, Pedro A.
Monjazeb, Arta M.
Mayadev, Jyoti
Finkelstein, Steven E.
Buatti, John M.
Patel, Sandip P.
Lin, Steven H.
LANCET ONCOLOGY, 2024, 25 (10) : E489 - E500
[3] Ghrelin, a novel therapy, corrects cytokine and NF-κB-AKT-MAPK network and mitigates intestinal injury induced by combined radiation and skin-wound trauma
Kiang, Juliann G.
Smith, Joan T.
Cannon, Georgetta
Anderson, Marsha N.
Ho, Connie
Zhai, Min
Cui, Wanchang
Xiao, Mang
CELL AND BIOSCIENCE, 2020, 10 (01)
[4] Ghrelin, a novel therapy, corrects cytokine and NF-κB-AKT-MAPK network and mitigates intestinal injury induced by combined radiation and skin-wound trauma
Juliann G. Kiang
Joan T. Smith
Georgetta Cannon
Marsha N. Anderson
Connie Ho
Min Zhai
Wanchang Cui
Mang Xiao
Cell & Bioscience, 10

← 1 →